All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 2, 2021
Home » Blogs » BioWorld MedTech Perspectives » Leverage: A tale of three struggles for power

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Leverage: A tale of three struggles for power

Dec. 13, 2013
By Mark McCarty
No Comments

Archimedes_leverWe all know power struggles are part of life, but not all struggles for leverage are created equal. Following are three stories that tell us something about leverage and its many uses.

Interagency conflict over Intermacs?

The Centers for Medicare & Medicaid Services recently announced it would no longer require hospitals to forward data from their patients with ventricular assist devices to the Intermacs registry. Depending on whom one asks, that’s a plus for hospitals, but the flip side of that particular coin is that another registry will have to take it’s place.

The problem with CMS seeming to pull the plug on Intermacs is that the National Institutes of Health also has a stake in the registry, and there’s not much indication NIH is also ready to pull the plug. NIH still publishes annual updates to the contents of the registry, such as this report published earlier this year in the Journal of Heart and Lung Transplantation.

Note also that the name Intermacs is an acronym for Interagency Registry for Mechanically Assisted Circulatory Support. Clearly there’s a big potential for a turf war here, especially given that most cardiologists think there’s still a need for a registry for ventricular assist devices.

Demurring on da Vinci

Intuitive Surgical has a raft of lawsuits on its hands over the use of the company’s surgical robot, the da Vinci, but a recent FDA report did not seem terribly incriminating of the device’s design or manufacture.

FDA announced Nov. 8 that it was “aware of an increase in the number of medical device reports” associated with computer-assisted surgical systems, stating that the majority of the reports the agency received “were of device malfunctions,” including “component breakage, mechanical problems and image/display issues.”

On the other hand, FDA also said that much of the up-tick in reports of injuries and deaths associated with the device may be due to “increased publicity resulting from product recalls, media coverage, and litigation.” The agency went as far as to say that adverse event reports “can contain incomplete, inaccurate, duplicative, and unverified information,” and that the mere filing of a report “does not necessarily indicate a faulty or defective medical device.”

Somehow one doubts seriously whether the trial bar will be even slightly put off by the news. One also wonders when some brave surgeon will admit he or she screwed up, and that it wasn’t the device’s fault at all.

Ah, doctors and lawyers. Amazing.

Aghast over Avandia

And finally, we note that FDA has withdrawn its restrictions on Avandia. FDA stated in its Nov. 25 announcement that the data from the Record trial “showed no elevated risk of heart attack or death in patients being treated with Avandia when compared to standard-of-care diabetes drugs.” FDA stated further that the data “do not confirm” the reports of a greater risk of heart attacks as described by Steve Nissen and Kathy Wolski in their study appearing in NEJM in 2007.

This is actually two tales. One tale is that of a medical stampede, not toward a drug or device, but away from a drug or device. Ironically, the molecular entity behind Avandia went off patent last year, so the news comes just in time for generics makers to cash in.

The second tale is that despite the fact that Nissen was clearly mistaken, he went full bore with a conspiracy theory argument in the Wall Street Journal earlier this year when FDA announced it would hold an advisory committee hearing on the drug. A conspiracy of common sense, one supposes, is no less a conspiracy.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 1.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing